 Tristan Huie
Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Idiopathic Pulmonary Fibrosis | 11 | 2025 | 633 | 1.740 |
Why?
| | Hemoptysis | 2 | 2023 | 35 | 1.060 |
Why?
| | Lung Diseases, Interstitial | 10 | 2017 | 610 | 0.840 |
Why?
| | Simulation Training | 1 | 2023 | 81 | 0.770 |
Why?
| | Education, Medical | 1 | 2023 | 244 | 0.690 |
Why?
| | Tomography, X-Ray Computed | 6 | 2025 | 2515 | 0.590 |
Why?
| | Alveolitis, Extrinsic Allergic | 4 | 2019 | 97 | 0.470 |
Why?
| | Physicians | 1 | 2023 | 859 | 0.470 |
Why?
| | Arthritis, Rheumatoid | 4 | 2017 | 1097 | 0.420 |
Why?
| | Emphysema | 1 | 2013 | 109 | 0.400 |
Why?
| | Pulmonary Fibrosis | 3 | 2012 | 384 | 0.390 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 1004 | 0.340 |
Why?
| | Clinical Competence | 3 | 2024 | 1016 | 0.290 |
Why?
| | Smoking | 2 | 2017 | 1499 | 0.280 |
Why?
| | Bronchoscopy | 2 | 2025 | 216 | 0.270 |
Why?
| | Anatomy | 1 | 2024 | 27 | 0.230 |
Why?
| | Connective Tissue Diseases | 3 | 2013 | 82 | 0.220 |
Why?
| | Virtual Reality | 1 | 2024 | 52 | 0.220 |
Why?
| | Patient Acuity | 1 | 2024 | 45 | 0.220 |
Why?
| | Endosonography | 1 | 2024 | 143 | 0.210 |
Why?
| | Teaching Rounds | 1 | 2024 | 68 | 0.200 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2025 | 644 | 0.190 |
Why?
| | Workload | 1 | 2024 | 153 | 0.190 |
Why?
| | Equipment Design | 1 | 2023 | 513 | 0.190 |
Why?
| | Lung | 6 | 2019 | 3927 | 0.190 |
Why?
| | Humans | 29 | 2025 | 129266 | 0.180 |
Why?
| | Computer Simulation | 1 | 2023 | 939 | 0.160 |
Why?
| | Cause of Death | 2 | 2019 | 392 | 0.160 |
Why?
| | Radiologists | 1 | 2019 | 41 | 0.160 |
Why?
| | Lung Transplantation | 2 | 2020 | 289 | 0.150 |
Why?
| | Sarcoidosis | 2 | 2011 | 156 | 0.150 |
Why?
| | Biomarkers | 1 | 2010 | 3968 | 0.150 |
Why?
| | Intensive Care Units | 1 | 2024 | 736 | 0.150 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2019 | 84 | 0.150 |
Why?
| | Curriculum | 1 | 2023 | 910 | 0.140 |
Why?
| | Mortality | 1 | 2019 | 307 | 0.130 |
Why?
| | Vital Capacity | 5 | 2017 | 291 | 0.130 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 372 | 0.130 |
Why?
| | Toll-Like Receptors | 1 | 2017 | 179 | 0.130 |
Why?
| | Common Variable Immunodeficiency | 1 | 2016 | 26 | 0.130 |
Why?
| | Male | 21 | 2025 | 63512 | 0.130 |
Why?
| | Cognition | 1 | 2024 | 1122 | 0.130 |
Why?
| | Granuloma | 1 | 2016 | 89 | 0.130 |
Why?
| | RNA Splicing | 1 | 2017 | 260 | 0.120 |
Why?
| | Alternative Splicing | 1 | 2017 | 216 | 0.120 |
Why?
| | Female | 21 | 2025 | 68551 | 0.120 |
Why?
| | Forced Expiratory Volume | 2 | 2015 | 510 | 0.120 |
Why?
| | Radiographic Image Enhancement | 1 | 2015 | 54 | 0.120 |
Why?
| | Registries | 2 | 2020 | 1895 | 0.120 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1432 | 0.120 |
Why?
| | Aged | 13 | 2025 | 22032 | 0.120 |
Why?
| | Medical History Taking | 1 | 2015 | 119 | 0.110 |
Why?
| | Middle Aged | 15 | 2025 | 31090 | 0.110 |
Why?
| | Leukocytes, Mononuclear | 1 | 2017 | 545 | 0.110 |
Why?
| | Survival Analysis | 3 | 2017 | 1269 | 0.110 |
Why?
| | Radiography, Thoracic | 1 | 2015 | 166 | 0.110 |
Why?
| | Surveys and Questionnaires | 2 | 2023 | 5384 | 0.110 |
Why?
| | Bronchiolitis Obliterans | 1 | 2013 | 68 | 0.100 |
Why?
| | Mycophenolic Acid | 1 | 2013 | 110 | 0.100 |
Why?
| | Bronchial Diseases | 1 | 2012 | 37 | 0.100 |
Why?
| | Lymphatic Vessels | 1 | 2012 | 61 | 0.100 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2013 | 363 | 0.100 |
Why?
| | Pulmonary Diffusing Capacity | 3 | 2017 | 74 | 0.090 |
Why?
| | Respiratory Function Tests | 4 | 2014 | 583 | 0.090 |
Why?
| | Collagen | 1 | 2012 | 433 | 0.090 |
Why?
| | Peptides, Cyclic | 1 | 2012 | 256 | 0.090 |
Why?
| | RNA, Messenger | 1 | 2017 | 2703 | 0.080 |
Why?
| | Gastroesophageal Reflux | 1 | 2012 | 232 | 0.080 |
Why?
| | Severity of Illness Index | 2 | 2019 | 2740 | 0.080 |
Why?
| | Aged, 80 and over | 5 | 2012 | 7055 | 0.080 |
Why?
| | Pulmonary Embolism | 1 | 2011 | 211 | 0.080 |
Why?
| | United States | 8 | 2020 | 13826 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 3 | 2015 | 851 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2013 | 854 | 0.070 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2012 | 275 | 0.070 |
Why?
| | Fibroblasts | 1 | 2012 | 948 | 0.070 |
Why?
| | Multivariate Analysis | 3 | 2016 | 1497 | 0.070 |
Why?
| | Acute Lung Injury | 1 | 2010 | 279 | 0.070 |
Why?
| | Disease Progression | 3 | 2020 | 2630 | 0.070 |
Why?
| | Respiratory Insufficiency | 1 | 2010 | 313 | 0.070 |
Why?
| | Retrospective Studies | 5 | 2025 | 14461 | 0.060 |
Why?
| | Survival Rate | 3 | 2015 | 1869 | 0.060 |
Why?
| | Biopsy | 3 | 2014 | 1092 | 0.060 |
Why?
| | Proportional Hazards Models | 2 | 2020 | 1197 | 0.060 |
Why?
| | Autoantibodies | 1 | 2012 | 1467 | 0.060 |
Why?
| | Signal Transduction | 1 | 2017 | 4926 | 0.050 |
Why?
| | ROC Curve | 1 | 2025 | 503 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2024 | 521 | 0.050 |
Why?
| | Radiography | 2 | 2016 | 796 | 0.050 |
Why?
| | Case-Control Studies | 3 | 2016 | 3377 | 0.050 |
Why?
| | Sex Distribution | 2 | 2012 | 359 | 0.040 |
Why?
| | Genomics | 1 | 2025 | 717 | 0.040 |
Why?
| | Occupations | 1 | 2019 | 42 | 0.040 |
Why?
| | Risk Factors | 4 | 2016 | 9745 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2019 | 110 | 0.040 |
Why?
| | Logistic Models | 2 | 2016 | 1985 | 0.040 |
Why?
| | Biological Specimen Banks | 1 | 2019 | 97 | 0.040 |
Why?
| | Forecasting | 1 | 2019 | 359 | 0.030 |
Why?
| | Prognosis | 2 | 2017 | 3773 | 0.030 |
Why?
| | Idiopathic Interstitial Pneumonias | 1 | 2017 | 49 | 0.030 |
Why?
| | Hypersplenism | 1 | 2016 | 7 | 0.030 |
Why?
| | Leukopenia | 1 | 2016 | 28 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2014 | 2715 | 0.030 |
Why?
| | RNA Precursors | 1 | 2017 | 147 | 0.030 |
Why?
| | Rheumatoid Factor | 1 | 2017 | 166 | 0.030 |
Why?
| | Arthritis | 1 | 2016 | 90 | 0.030 |
Why?
| | Internship and Residency | 1 | 2024 | 1047 | 0.030 |
Why?
| | Prospective Studies | 2 | 2020 | 7123 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1544 | 0.030 |
Why?
| | Alberta | 1 | 2013 | 14 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor D | 1 | 2012 | 13 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor C | 1 | 2012 | 17 | 0.030 |
Why?
| | Lymphangiogenesis | 1 | 2012 | 26 | 0.030 |
Why?
| | Patient Dropouts | 1 | 2013 | 64 | 0.030 |
Why?
| | Cohort Studies | 2 | 2015 | 5409 | 0.020 |
Why?
| | Pulmonary Gas Exchange | 1 | 2012 | 120 | 0.020 |
Why?
| | Databases, Factual | 1 | 2016 | 1266 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2012 | 541 | 0.020 |
Why?
| | Adult | 4 | 2016 | 35495 | 0.020 |
Why?
| | Age Distribution | 1 | 2011 | 372 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 514 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2012 | 530 | 0.020 |
Why?
| | Cytokines | 1 | 2017 | 2013 | 0.020 |
Why?
| | Exercise | 1 | 2020 | 1925 | 0.020 |
Why?
| | Risk | 1 | 2011 | 854 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2008 | 299 | 0.020 |
Why?
| | Chronic Disease | 1 | 2013 | 1716 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 1965 | 0.020 |
Why?
| | Inflammation | 1 | 2017 | 2737 | 0.020 |
Why?
| | Acute Disease | 1 | 2008 | 978 | 0.020 |
Why?
| | Young Adult | 2 | 2012 | 12391 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2013 | 4887 | 0.010 |
Why?
| | Time Factors | 1 | 2013 | 6543 | 0.010 |
Why?
| | Adolescent | 1 | 2011 | 20313 | 0.010 |
Why?
|
|
Huie's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|